provide important benefits such as decreased nonspecific
binding. Incorporation of nonnatural residues also discour-
ages decomposition of peptides in vivo.6 Given the high cost
of Dap, and our desire to incorporate this residue into
multiple positions within polypeptides, we have developed
an efficient and economical route to a protected form of Dap.
Extensive studies using Dap can be limited due to the cost
associated with purchasing this compound. Although com-
mercially available, the typical price for Dap (with orthogonal
protecting groups) is about $35/mmol.7 This cost can be
prohibitive when using an excess of monomer in the solid-
phase synthesis of a polypeptide containing multiple Dap
residues. Furthermore, only the L-enantiomer is available
commercially.
encountered were the constant need to exchange protecting
groups, the high cost of bis-[trifluoroacetoxy]-iodo benzene
(∼$0.95/mmol11), and the requirement to use an excess (at
least 2 equiv) of this reagent. Therefore, we began to develop
a more direct and less costly route to Dap.
We felt that a Curtius rearrangement of an aspartic acid
derivative would afford an isocyanate that could be trapped
with benzyl alcohol to directly afford a derivative of Dap
with orthogonal protecting groups suitable for solid-phase
peptide synthesis. Starting from Boc-Asp-OBn (1), a Curtius
1
rearrangement proceeded to give a product with H NMR
consistent with the expected isocyanate intermediate 2
(Figure 3). To our surprise, multiple efforts to trap the
The most common synthesis of Dap involves a Hoffman
rearrangement of protected asparagine using a trivalent iodine
reagent, most often bis-[trifluoroacetoxy]-iodo benzene
(Figure 2). When this reagent is used, the trifluoroacetic acid
Figure 3. Cyclization with a single Boc-protecting group during
Curtius rearrangement.
Figure 2. Hoffman rearrangement with bis-[trifluoroacetoxy]-iodo
benzene.12
supposed isocyante failed. Additional 13C NMR, IR, and mass
spectrometry data confirmed that cyclic urea 3 was present
instead. In the 1H NMR of 3, the urea proton (H*) appeared
in the same region (5.3-5.6 ppm in CDCl3) as most
carbamate protons, which was initially deceptive. Also, there
was no discernible change in the couplings or chemical shifts
of the R or â protons to indicate urea versus isocyanate
formation. Deprotection of the Boc group from 3 provided
the unprotected urea, which was also fully characterized. A
number of studies have shown that carbamate-protected
amines can trap isocyanates via intramolecular cyclization.13
In our case, the cyclization to form a five-membered ring
urea was especially efficient. We were unable to intercept
the isocyanate with other nucleophiles.
We were able to prevent the intramolecular trapping of
the isocyanate after the Curtius rearrangement by dually
protecting the reactive nitrogen.14 Starting from protected
aspartic acid 4, which is commercially available, the car-
boxylic acid was first converted to methyl ester 5, followed
by introduction of a second Boc group13a to give 6 (Scheme
formed in solution8 is believed to catalyze the hydrolysis of
the isocyanate intermediate to an amine, reducing urea
formation from reaction of amine with remaining isocyanate.9
However, the acid generated can also remove a Boc
protecting group. As shown in Figure 2, Boc-protected
asparagine produced significantly lower yields than Cbz-
protected asparagine when subjected to the same conditions
for the Hoffman rearrangement. Fmoc-protected asparagine
had poor solubility under the same reaction conditions, which
accounts for the failure of the Hoffman rearrangement when
using this form of protected asparagine. If Cbz protection is
used, which is optimal, then an R-amine protecting group
must be converted to a Boc or Fmoc group in order to be
compatible with solid-phase peptide synthesis.10 Because we
required access to large amounts of Boc-protected Dap, the
Hoffman-based synthesis of Dap quickly became prohibitive
to the progress of our research. The main problems we
(5) Battiste, J. L.; Mao, H.; Rao, N. S.; Tan, R.; Mahandiram, D. R.;
Kay, L. E.; Frankel, A. D.; Williamson, J. R. Science 1996, 273, 1547.
(6) Gante, J. Angew. Chem., Int. Ed. Engl. 1994, 33, 1669.
(7) Advanced ChemTech, Louisville, KY.
(8) Boutin, R. H.; Loundon, G. M. J. Org. Chem. 1984, 49, 4277.
(9) Radhakrishna, A. S.; Parham, M. E.; Riggs, R. M.; Loundon, G. M.
J. Org. Chem. 1979, 44, 1746.
(11) Aldrich, Milwaukee, WI.
(12) Waki, M.; Kitajima, Y.; Izumiya, N. Synthesis 1981, 4, 266.
(13) (a) Theon, J. C.; Morales-Ramos, A. I.; Lipton, M. A. Org. Lett.
2002, 4, 4455. (b) Salituro, F. G.; Agarwal, N.; Hofmann, T.; Rich, D. H.
J. Med. Chem. 1987, 30, 286. (c) Bodanszky, M.; Ondetti, M. A. Peptide
Synthesis; Interscience Pubpishers: New York, 1966; Chapter 5.
(14) Roberts, J. L.; Chan, C. Tetrahedron Lett. 2002, 43, 7679.
(10) Arttamangkul, S.; Murray, T. F.; DeLander, G. E.; Aldrich, J. V. J.
Med. Chem. 1995, 38, 2410.
214
Org. Lett., Vol. 6, No. 2, 2004